MGC Pharmaceuticals - Appointment of Non-Executive Director

Argent BioPharma

01/06/2023 07:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230601:nRSA3212Ba&default-theme=true

RNS Number : 3212B  MGC Pharmaceuticals Limited  01 June 2023

1 June 2023

ASX Code: MXC

LSE Code: MXC

 

Appointment of Non-Executive Director

 

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based
pharmaceutical company specialising in the production and development of plant
inspired medicines, is pleased to announce the appointment of Mr. Layton Mills
as a Non-Executive Director of the Company effective immediately.

 

Mr. Mills is an experienced life-sciences executive, having worked in the
biotechnology and life sciences industries for over 15 years, developing
significant experience across human and animal health in pharmaceutical and
consumer healthcare.

 

Mr. Mills is the founder of CannPal Animal Therapeutics Pty Ltd, an Animal
Health Company developing cannabinoid-based veterinary medicines for FDA-CVM
registration, which he led through an Initial Public Offering on the
Australian Stock Exchange, followed by an acquisition by AusCann Group
Holdings in 2021 where he served as CEO. Mr Mills is also the founder and
Managing Director of Subgenix Lifesciences, an early-stage biotechnology
Company using conventional drug development strategies to unlock the broader
therapeutic potential of psychedelic compounds for rare and underserved health
needs.

 

He has extensive international business experience having been involved in
corporate business activities across Europe, Asia and North America, including
government-led trade incentives with the Canberra Business Chamber.

 

-Ends-

 

Authorised for release by the board of directors, for further information
please contact:

 MGC Pharmaceuticals Ltd                                                     MGC Pharmaceuticals Ltd

 Roby Zomer                                                                  Arron Canicais / Rowan Harland

 CEO & Managing Director                                                     Joint Company Secretaries

 +61 8 6382 3390                                                             +61 8 6382 3390

 info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)                          info@mgcpharma.co.uk (mailto:info@mgcpharma.co.uk)
 UK Brokers                                                                  UK Brokers

 Peterhouse Capital                                                          Oberon Capital

 Charles Goodfellow / Lucy Williams / Duncan Vasey                           Aimee McCusker / Adam Pollock

 +44 207 469 0930                                                            +44 203 179 5300

 cg@peterhousecap.com (mailto:cg@peterhousecap.com) / lw@peterhousecap.com   aimeemccusker@oberoninvestments.com
 (mailto:lw@peterhousecap.com)                                               (mailto:aimeemccusker@oberoninvestments.com) adampollock@oberoninvestments.com
                                                                             (mailto:adampollock@oberoninvestments.com)
 UK IR/PR Advisers

 IFC Advisory

 Graham Herring / Tim Metcalfe / Zach Cohen

 +44 203 934 6630

 mgcpharma@investor-focus.co.uk (mailto:mgcpharma@investor-focus.co.uk)

 

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based
pharmaceutical company, focused on developing and supplying accessible and
ethically produced plant inspired medicines, combining in-house research with
innovative technologies, with the goal of finding or producing treatments to
for unmet medical conditions.

 

The Company's founders and executives are key figures in the global
pharmaceuticals industry and the core business strategy is to develop and
supply high quality plant inspired medicines for the growing demand in the
medical markets in Europe, North America and Australasia.

 

MGC Pharma has a robust development pipeline targeting two widespread medical
conditions and has further products under development.

 

MGC Pharma has partnered with renowned institutions and academia to optimise
the development of targeted plant inspired medicines, to be produced in the
Company's EU-GMP Certified manufacturing facilities.

 

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland
and has a global distribution footprint via an extensive network of commercial
partners meaning that it is poised to supply the global market.

 

Follow us through our social media channels:

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZZGGVVMGGFZG